Double Medical Technology (SZSE:002901) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Double Medical Technology (SZSE:002901) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Double Medical Technology Inc.'s (SZSE:002901) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerning in the numbers.
大博醫療(SZSE:002901)的強勁收益報告未能推動其股票市場的變化。我們的分析表明,股東們注意到了數字中的一些問題。
The Impact Of Unusual Items On Profit
非正常項目對利潤的影響
For anyone who wants to understand Double Medical Technology's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥48m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Double Medical Technology's positive unusual items were quite significant relative to its profit in the year to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
對於任何想要了解大博醫療利潤的讀者,除了一般的法定數字外,需要注意的是,在過去的十二個月,法定利潤受益於4800萬元的非常項。我們不能否認,較高的利潤通常讓我們感到樂觀,但我們更希望這種利潤是可持續的。當我們對成千上萬的上市公司進行分析時,我們發現某一年來自非常項目的提升,通常在下一年是不再出現的。這並不令人感到意外,畢竟其名稱就是如此。我們可以看到大博醫療在截至2024年9月的年度中,其正面的非常項目相對於其利潤而言是相當顯著的。因此,我們可以推測,這些非常項目使其法定利潤顯著強於其他情況下的狀態。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能讓你想知道分析師對於未來盈利能力的預測。幸運的是,你可以點擊這裏查看一個基於他們的估算的未來盈利能力的互動圖表。
Our Take On Double Medical Technology's Profit Performance
我們對Double Medical Technology的盈利表現看法
As we discussed above, we think the significant positive unusual item makes Double Medical Technology's earnings a poor guide to its underlying profitability. For this reason, we think that Double Medical Technology's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Double Medical Technology has 2 warning signs and it would be unwise to ignore them.
正如我們上面討論的,我們認爲重大正向非常規項目使得大博醫療的收益無法準確反映其潛在盈利能力。因此,我們認爲大博醫療的法定利潤可能對其潛在盈利能力的指導性不強,可能會給投資者對公司的印象過於積極。好的一面是,公司在今年有了足夠的改善,能夠盈利,而去年則是虧損。本文的目標是評估我們對法定收益在反映公司潛力方面的可靠程度,但還有很多其他因素需要考慮。因此,如果您希望對公司進行更多分析,了解相關風險至關重要。在我們的分析中,我們發現大博醫療存在兩個警告信號,忽視它們是不明智的。
Today we've zoomed in on a single data point to better understand the nature of Double Medical Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天我們聚焦於一個單獨的數據點,以更好地理解大博醫療的利潤性質。但如果您能夠專注於細節,總會有更多的發現。例如,許多人認爲高股本回報率是良好商業經濟的指標,而另一些人則喜歡"追蹤資金",尋找內部人士正在購買的股票。雖然這可能需要您進行一些研究,但您可能會發現這份包含高股本回報率公司的免費清單或這份內部持股顯著的股票列表是有用的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。